| Metric | Q3 FY26 | Q2 FY26 | Q2 FY25 |
|---|---|---|---|
| Other income | 5.1 | 0.7 | 0.0 |
| Total income | 186.0 | 13.4 | 0.0 |
| Net profit | 12.9 | -2.1 | -0.7 |
| Operating margin | 9.1% | -15.7% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: KRATOSENER. Figures extracted from the filing.
Lords Mark Industries Ltd: key numbers
- Share price
- ₹84.93
- Market cap
- ₹3,623 Cr
- Revenue (annual)
- ₹684.8 Cr
- Net profit (annual)
- ₹48.59 Cr
- P/E (TTM)
- 43.4×Sector 21.5×
- Promoter holding
- 79.84%-1.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lords Mark Industries Ltd
All →Lords Mark Industries Business Update
Promoter Sachidanand Hariram Upadhyay proposed reinvesting proceeds from his prior sale of shares into the company's medical device unit expansion.
- Value
- ₹87.38 Cr
Lords Mark Industries Business Update
Lord’s Mark Industries has advanced its AI-powered breast cancer screening technology to final clinical trial stages. The company targets a global commercial launch by April 2027.
Lords Mark Industries Promoter Selling: ₹87.39 Cr
Promoter Director Mr. Sachidanand H Upadhyay sold 1.04 crore shares on BSE for ₹87.39 Crore. Stake reduced from 77.54% to 75.11%.
- Value
- ₹87.39 Cr
Lords Mark Industries Promoter Selling
Lord's Mark promoter Sachidanand Upadhyay disposed 1.04 crore shares via open market, cutting his stake from 77.54% to 75.11%.
Lords Mark Industries Capacity Expansion
Lord's Mark Industries completed Phase I Silvassa expansion, adding 18 surgical/orthopaedic SKUs (36 to 54). Commercial operations commence October 11, 2026.
- surgical and orthopaedic product SKUs
- 54 SKUs
Lords Mark Industries Investor Presentation: Key Takeaways
Lord's Mark Industries is a MedTech and Renewable Energy conglomerate focused on high-margin diagnostic innovations and a ₹3,000+ Cr solar order pipeline.